{"id":41210,"title":"Protocol : Cement augmentation of internal fixation for trochanteric fracture: protocol for a systematic review and meta-analysis","title_html":"<p>Protocol : Cement augmentation of internal fixation for trochanteric fracture: protocol for a systematic review and meta-analysis<\/p>","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.bkg2ktye","doi_status":2,"uri":"protocol-cement-augmentation-of-internal-fixation-bkg2ktye","type_id":4,"template_id":3,"published_on":1598709511,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":5,"created_on":1598709379,"categories":null,"creator":{"name":"Norio Yamamoto","affiliation":null,"affiliations":[],"username":"norio-yamamoto","note":null,"link":null,"image":{"source":"\/img\/avatars\/005.png","placeholder":"\/img\/avatars\/005.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"public":1,"has_versions":0,"link":null,"total_collections":0,"number_of_steps":0,"authors":[{"name":"Norio Yamamoto","affiliation":"Department of Orthopedic Surgery, Kagawa Prefectural Central Hospital, Kagawa, Japan","affiliations":[],"username":"norio-yamamoto","note":null,"link":null,"image":{"source":"\/img\/avatars\/005.png","placeholder":"\/img\/avatars\/005.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Takahisa Ogawa","affiliation":"Department of Orthopedic Surgery, Tokyo Medical and Dental University, Tokyo, Japan","affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Masahiro Banno","affiliation":"Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan","affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Jun Watanabe","affiliation":"Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan","affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Tomoyuki Noda","affiliation":"Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan","affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":" Haggai Schermann","affiliation":"Department of orthopedics ,Foot and Ankle Research and Innovation Laboratory, Massachusetts General Hospital, Boston, USA","affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Toshifumi Ozaki","affiliation":"Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan","affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[],"is_owner":1,"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_claim_authorship":0,"can_accept_authorship":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"url":"https:\/\/www.protocols.io\/view\/protocol-cement-augmentation-of-internal-fixation-bkg2ktye","forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"EDC2AF7E62F7415EACD7FD144AB3B3A3","state_version_id":1,"steps":[],"document":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Title:<\/span><span> Protocol : Cement augmentation of internal fixation for trochanteric fracture: protocol for a systematic review and meta-analysis<\/span><\/div><div class = \"text-block\">Norio Yamamoto MD1,2, Takahisa Ogawa MD, MPH3, Masahiro Banno, MD, PhD2,4,5,<\/div><div class = \"text-block\">Jun Watanabe MD, PhD2, 6, 7, Tomoyuki Noda, MD, PhD8, Haggai Schermann, MD, MPH9Toshifumi Ozaki, MD, PhD10<\/div><div class = \"text-block\">1 Department of Orthopedic Surgery, Kagawa Prefectural Central Hospital, Kagawa, Japan<\/div><div class = \"text-block\">2 Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">3 Department of Orthopedic Surgery, Tokyo Medical and Dental University, Tokyo, Japan<\/div><div class = \"text-block\">4 Department of Psychiatry, Seichiryo Hospital, Tsurumai 4-16-27, Showa-ku, Nagoya 466-0064 JAPAN<\/div><div class = \"text-block\">5 Department of Psychiatry, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8560 JAPAN<\/div><div class = \"text-block\">6 Department of Surgery, Tottori Prefectural Central Hospital, 730 Ezu Tottori City, Tottori, 680-0901 Japan<\/div><div class = \"text-block\">7 Center for Community Medicine, Jichi Medical University, 3311-1 Yakushiji Shimotsuke City, Tochigi, 329-0498 Japan<\/div><div class = \"text-block\">8 Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan<\/div><div class = \"text-block\">9 Department of orthopedics ,Foot and Ankle Research and Innovation Laboratory,<\/div><div class = \"text-block\">Massachusetts General Hospital, Boston, USA<\/div><div class = \"text-block\">10 Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan<\/div><div class = \"text-block\">Corresponding author: Norio YAMAMOTO, MD<\/div><div class = \"text-block\">Department of Orthopedic Surgery, Kagawa Prefectural Central Hospital, Kagawa, Japan<\/div><div class = \"text-block\">1-2-1, Asahi-machi, Takamatsu, Kagawa 760-8557, Japan<\/div><div class = \"text-block\">Tel.: +81 87 811 3333; Fax: +81 87 802 1188<\/div><div class = \"text-block\">E-mail: norio-yamamoto@umin.ac.jp<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">1.Introduction<\/span><\/div><div class = \"text-block\">Demographic development has resulted in an increased incidence of geriatric hip fractures [1, 2].Patients with hip fractures becoming older and increasingly frail [2]. More trochanteric fractures than neck fractures among hip fractures occurred [1, 2]. Trochanteric fractures lead to increased mortality and a significant socio-economic burden [3]. To prevent complications of immobilization, rigid fracture fixation should allow early mobilization of the patient with immediate full weight bearing.<\/div><div class = \"text-block\">There are some complications for internal fixation, such as screw cut out, cut through, which results in reoperation. The mechanical failure is due to instability by breakdown of the interface between femoral head and lag screw, caused by combined axial loads and rotational moments during walking gait [4, 5, 6]. Recent reports suggested that the cement enhances the implant anchorage within the head-neck fragment and leads to good functional results with less complications [7, 8]. However, it still remains unclear whether the cement augmentation could be a better fixation option when compared with conventional internal fixation alone.<\/div><div class = \"text-block\">The purpose of this study is to determine the efficacy and safety of cement augmentation for internally-fixed trochanteric fractures using a systematic review and meta-analysis.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">2.Research question<\/span><\/div><div class = \"text-block\">P: Patient with internal fixation for trochanteric fracture<\/div><div class = \"text-block\">I: \u201dConventional internal fixation\" plus \"cement augmentation\u201d<\/div><div class = \"text-block\">C: \u201dConventional internal fixation\" plus \"sham interventions or non-intervention or usual care\u201d<\/div><div class = \"text-block\">O: Fixation failures, Parker Mobility Score, 1-year mortality rate, EQ-5D (Functional outcomes: patient-reported measures of hip function), and adverse events<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.Method<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.1 Inclusion criteria of the articles for the review<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.1.1 Type of studies<\/span><\/div><div class = \"text-block\">We will include randomised controlled trials that assess cement augmentation on internal fixation for trochanteric fracture. We will not apply language or country restrictions. We will include all papers including published, unpublished articles, abstract of conference and letter.<\/div><div class = \"text-block\">We will exclude crossover trials,quasi-experimental studies and quasi-randomized trials. We will not exclude studies based on the observation period.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.1.2  Study participants<\/span><\/div><div class = \"text-block\">Patients who has sustained trochanteric fracture and undergoes internal fixation as operative treatment<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Inclusion criteria:<\/span><\/div><div class = \"text-block\">Fracture type: Arbeitsgemeinschaft f\u00fcr Osteosynthesefragen\/Orthopedic Trauma Association (AO\/OTA) classification 31A [9].<\/div><div class = \"text-block\">The ability to walk with or without supportbefore the fracture.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Exclusion criteria:<\/span><\/div><div class = \"text-block\">Pathological fractures, open fractures, history of allergy to cement<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.1.3 Intervention<\/span><\/div><div class = \"text-block\">\u201cConventional internal fixation\" plus \"cement augmentation\u201d<\/div><div class = \"text-block\">Cement will be inserted into or around the screw.<\/div><div class = \"text-block\">Type of cement: For example, calcium phosphate degradable cement, polymethyl methacrylate (PMMA) cement. We do not set type of cement restrictions.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.1.4 Control<\/span><\/div><div class = \"text-block\">\"Conventional internal fixation\" plus \"sham interventions or non-intervention or usual care\"<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.2 Type of outcomes<\/span><\/div><div class = \"text-block\"><span>3.2.1 <\/span><span style = \"font-weight:bold;\">Primary outcomes<\/span><\/div><div class = \"text-block\">1. Reoperation<\/div><div class = \"text-block\">Definition: Indication of reoperations are set by original authors<\/div><div class = \"text-block\">Incidence proportion of reoperation<\/div><div class = \"text-block\">Period: during follow up period<\/div><div class = \"text-block\">2. Ability of mobility<\/div><div class = \"text-block\">Definition: Parker Mobility Score [10]<\/div><div class = \"text-block\">Period: between 3 and 12 months follow up ( at the longest follow up from 3 months follow up)<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.2.2 Secondary outcomes<\/span><\/div><div class = \"text-block\">1. 1-year mortality rate<\/div><div class = \"text-block\">Definition: incidence proportion of death during 1-year follow up period<\/div><div class = \"text-block\">Period: during 1-year follow up period<\/div><div class = \"text-block\">2. Functional outcomes: patient-reported measures of hip function<\/div><div class = \"text-block\">Definition: EuroQoL 5 dimensions (EQ-5D)  3-level (3L) [11] or 5-level (5L) [12, 13]<\/div><div class = \"text-block\">Period: between 3 and 12 months follow up ( at the longest follow up from 3 months follow up)<\/div><div class = \"text-block\">3. All adverse events<\/div><div class = \"text-block\">Definition: definition of adverse events are set by original authors.<\/div><div class = \"text-block\">Incidence proportion of all adverse events<\/div><div class = \"text-block\">Period: during follow up period<\/div><div class = \"text-block\">4. Fixation failures<\/div><div class = \"text-block\">Definition: Screw cut-out, penetration of the implant into the hip joint, loosening, implant breakage, non-union, and prominent screw by over sliding distance, for which reoperation is indicated or performed.<\/div><div class = \"text-block\">The definition of the fixation failure will be set by the authors of the original study.<\/div><div class = \"text-block\">Incidence proportion of all fixation failures<\/div><div class = \"text-block\">Period: during follow up period<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.3 Search method<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.3.1 Electronic search<\/span><\/div><div class = \"text-block\">We will search the following databases:<\/div><div class = \"text-block\">1.  the Cochrane Central Register of Controlled Trials(CENTRAL) ;<\/div><div class = \"text-block\">2.  MEDLINE via Pubmed<\/div><div class = \"text-block\">3.  EMBASE via PROQUEST<\/div><div class = \"text-block\">See Appendix 1, 2, and 3 for the search strategies.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.3.2 Other resources<\/span><\/div><div class = \"text-block\">We will also search the following databases for ongoing or recently completed trials:<\/div><div class = \"text-block\">1. the World Health Organization International Clinical Trials Platform Search Portal ( ICTRP)<\/div><div class = \"text-block\">2. ClinicalTrials.gov.<\/div><div class = \"text-block\">See Appendix 4, 5 for the search strategies.<\/div><div class = \"text-block\">We will check the reference lists of studies, including international guidelines [14, 15] as well as the reference lists of eligible studies and articles citing eligible studies. We will ask the authors of original studies for unpublished or additional data.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.4 Data extraction<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.4.1 Selection of the studies<\/span><\/div><div class = \"text-block\">Two independent reviewers (NY,TO, and HS) will screen every title and abstract of the articles. Articles extracted by reviewers will be included in the full text review. Each reviewer will independently perform study selection. We will make contact with original authors if there is any disagreement regarding the articles. The two reviewers will compare their lists and any differences in opinion will be resolved by discussion or, if necessary by consulting the third reviewer (JW).<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.4.2 Data extraction and management<\/span><\/div><div class = \"text-block\">Two reviewers (NY and TO) will perform independent data extraction of the included trials using data collection form, which is pre-checked by ten randomly selected studies. The data collected will include information on study design, study population, interventions and outcomes, and results. Any disagreements regarding the data extraction will be resolved by discussion or, if necessary by consulting a third reviewer (JW).<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.5 Risk of bias<\/span><\/div><div class = \"text-block\">Two reviewers (NY and TO) will assess risk of bias independently. We will use the Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) tool. Any disagreements regarding the risk of bias will be resolved by discussion or, if necessary by consulting a third reviewer (JW).<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.6 Assessment of the treatment effect<\/span><\/div><div class = \"text-block\">We will perform meta-analysis and calculate relative risk and 95% confidence intervals (CIs) about the following bivariate variables: fixation failures, 1-year mortality rate.<\/div><div class = \"text-block\">We will perform meta-analysis and calculate mean difference (MD) and 95% Cl about the following continuous variables: Parker Mobility Score, EQ-5D.<\/div><div class = \"text-block\">We will summarize adverse events based on the definition by the original article, but we will not perform meta-analysis..<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.7 Method of synthesis<\/span><\/div><div class = \"text-block\">We will analyse the mean and standard deviation of continuous data based on the method by Cochrane handbook [16]. For the functional outcome such as Parker Mobility Score or EQ-5D, we will define the functional outcome as the score assessed at the longer follow up period after the intervention. We will include the cluster-randomised trials that report an estimate of the intracluster (or intraclass) correlation coefficient (ICC) in meta-analysis.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.8Handling of missing data<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.8.1 Missing participants<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">For dichotomous data<\/span><\/div><div class = \"text-block\">We will perform the intention-to-treat (ITT) analysis for all dichotomous data as much as possible. We will also include missing participants for analysis.<\/div><div class = \"text-block\">For those dropped out from the study early, they are assumed to have the same rates of negative outcome on the basis of the rates of those who completed the study.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">For continuous data<\/span><\/div><div class = \"text-block\">We will not impute missing data based on the recommendation by Cochrane handbook [16]. We will perform meta-analysis about the available data in the original study.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.8.2Missing values<\/span><\/div><div class = \"text-block\">We will ask missing values to the original authors.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.8.3Missing statistics<\/span><\/div><div class = \"text-block\">When original studies only report standard error or p-value, we will calculate the standard deviation based on the method by Altman [17]. If we don't know these values when we contact the authors, standard deviation will be calculated by confidence interval and t-value based on the method by Cochrane handbook [16], or validated method [18]. Validity of these methods will be analysed by sensitivity analysis.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.9 Assessment of heterogeneity<\/span><\/div><div class = \"text-block\"><span>We will evaluate the statistical heterogeneity by visual inspection of the forest plots and calculating the I<\/span><span style = \"vertical-align:super;\">2<\/span><span> statistic (I<\/span><span style = \"vertical-align:super;\">2<\/span><span> values of 0% to 40%: might not be important; 30%to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity). When there is substantial heterogeneity (I<\/span><span style = \"vertical-align:super;\">2<\/span><span>> 50%), we will assess the reason of the heterogeneity. Cochrane Chi<\/span><span style = \"vertical-align:super;\">2<\/span><span>test (Q-test) will be performed for I<\/span><span style = \"vertical-align:super;\">2<\/span><span> statistic, and P value less than 0.10 will be defined as statistically significant.<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.10 Assessment of reporting bias<\/span><\/div><div class = \"text-block\">We will search the clinical trial registry system (ClinicalTrials.gov and  ICTRP) and will perform extensive literature search for unpublished trials. We will assess the potential publication bias by visual inspection of the funnel plot. Egger test will be performed as well. We will not conduct the test when we find less than 10 trials or trials which have similar sample size.We will assess the potential publication bias by visual inspection of the funnel plot<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.11 Meta-analysis<\/span><\/div><div class = \"text-block\">Meta-analysis will be performed using Review Manager software (RevMan 5.4). We will use a random-effects model.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.12 Subgroup analysis<\/span><\/div><div class = \"text-block\">To elucidate the influence of effect modifiers on results, we will evaluate the subgroup analyses of the primary outcomes on the following factors when sufficient data are available.<\/div><div class = \"text-block\">1. (For participants) Type of fracture: subgroups will be AO\/OTA classification 31A1, A2, A3<\/div><div class = \"text-block\">2. (For participants)  Type of implant used for internal fixation: subgroups will be intramedullary nailing and extramedullary implant (such as sliding hip screw).<\/div><div class = \"text-block\">3. (For intervention)Type of cement augmentation: subgroups will be calcium phosphate degradable cement, PMMA cement, and similar substances.<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">3.13 Sensitivity analysis<\/span><\/div><div class = \"text-block\">We will undertake sensitivity analyses for the primary outcome to assess whether the results of the review are robust to the decisions made during the review process. We plan to examine the effects of the review findings of:<\/div><div class = \"text-block\">1. Exclusion of studies using imputed statistics.<\/div><div class = \"text-block\">2. Missing participants: verify the robustness of the results by seeking informative missingness odds ratios.<\/div><div class = \"text-block\">3. Only the participants who complete the study with complete data<\/div><div class = \"text-block\">4.. Measurement-period adjustment: The functional outcome, such as Parker Mobility Score, EQ-5D, assessed at 1 year follow up<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">4. Summary of findings table<\/span><\/div><div class = \"text-block\">Summary of findings table will be made for the following outcome based on the Cochrane handbook [16].<\/div><div class = \"text-block\">We will include grading to evaluate the quality of evidence based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach for each Summary of findings table [16, 19].<\/div><div class = \"text-block\">1. Fixation failures<\/div><div class = \"text-block\">2. Parker Mobility Score<\/div><div class = \"text-block\">3. 1-year mortality rate<\/div><div class = \"text-block\">4. EQ-5D<\/div><div class = \"text-block\">5. All adverse events<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">5. Conflict of Interest<\/span><\/div><div class = \"text-block\">The authors declare no conflicts of interests.<\/div><div class = \"text-block\">Appendix 1: CENTRAL search strategy<\/div><div class = \"text-block\">( [mh \u201cHip Fractures\u201d] OR [mh \u201cFracture Fixation, Internal\u201d] OR intertrochanteric fracture*:ti,ab OR  trochanteric fracture*:ti,ab OR pertrochanteric fracture*:ti,ab OR nail:ti,ab OR sliding hip screw*:ti,ab) AND ( [mh \u201cBone Cements\u201d] OR [mh Cementoplasty] OR [mh \u201cpolymethyl methacrylate\u201d] OR [mh \u201ccalcium phosphates\u201d] OR cement*:ti,ab OR polymethyl methacrylate:ti,ab OR calcium phosphates:ti,ab OR CaP*:ti,ab)<\/div><div class = \"text-block\">Appendix 2: MEDLINE (via PubMed)search strategy<\/div><div class = \"text-block\">#1 \u201cHip Fractures\u201d [mh]<\/div><div class = \"text-block\">#2 \u201cFracture Fixation, Internal\u201d [mh]<\/div><div class = \"text-block\">#3  intertrochanteric fracture* [tiab]<\/div><div class = \"text-block\">#4  intertrochanteric femoral fracture* [tiab]<\/div><div class = \"text-block\">#5  trochanteric fracture* [tiab]<\/div><div class = \"text-block\">#6  pertrochanteric fracture* [tiab]<\/div><div class = \"text-block\">#7 nail* [tiab]<\/div><div class = \"text-block\">#8  sliding hip screw* [tiab]<\/div><div class = \"text-block\">#9  #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8<\/div><div class = \"text-block\">#10 \u201cBone Cements\u201d [mh]<\/div><div class = \"text-block\">#11 Cementoplasty [mh]<\/div><div class = \"text-block\">#12 \u201cpolymethyl methacrylate\u201d [mh]<\/div><div class = \"text-block\">#13 \u201ccalcium phosphates\u201d [mh]<\/div><div class = \"text-block\">#14 cement* [tiab]<\/div><div class = \"text-block\">#15  polymethyl methacrylate [tiab]<\/div><div class = \"text-block\">#16 \u201ccalcium phosphates\u201d [tiab]<\/div><div class = \"text-block\">#17  #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16<\/div><div class = \"text-block\">#18 \u201cdrug therapy\u201d[sh]<\/div><div class = \"text-block\">#19 randomly[tiab]<\/div><div class = \"text-block\">#20 trial[tiab]<\/div><div class = \"text-block\">#21 groups[tiab]<\/div><div class = \"text-block\">#22 randomized[tiab]<\/div><div class = \"text-block\">#23 placebo[tiab]<\/div><div class = \"text-block\">#24 \u201crandomized controlled trial\u201d[pt]<\/div><div class = \"text-block\">#25 \u201ccontrolled clinical trial\u201d[pt]<\/div><div class = \"text-block\">#26 animals [mh]<\/div><div class = \"text-block\">#27 humans [mh]<\/div><div class = \"text-block\">#28 #18 OR #19 OR #20 OR #21 OR #24 OR #25 OR #26 OR #27 NOT (#26 NOT #27)<\/div><div class = \"text-block\">#29 #9 AND #17 AND #28<\/div><div class = \"text-block\">Appendix 3: EMBASE search strategy<\/div><div class = \"text-block\">S1 (EMB.EXACT.EXPLODE(\"hip fracture\"))<\/div><div class = \"text-block\">S2  EMB.EXACT.EXPLODE(\"osteosynthesis\")<\/div><div class = \"text-block\">S3 (ab(intertrochanteric fracture) OR ti(intertrochanteric fracture) OR ab(intertrochanteric fractures) OR ti(intertrochanteric fractures))<\/div><div class = \"text-block\">S4 (ab(intertrochanteric femoral fracture) OR ti(intertrochanteric femoral fracture) OR ab(intertrochanteric femoral fractures) OR ti(intertrochanteric femoral fractures))<\/div><div class = \"text-block\">S5 (ab(trochanteric fracture) OR ti(trochanteric fracture) OR ab(trochanteric fractures) OR ti(trochanteric fractures))<\/div><div class = \"text-block\">S6 (ab(pertrochanteric fracture) OR ti(pertrochanteric fracture) OR ab(pertrochanteric fractures) OR ti(pertrochanteric fractures))<\/div><div class = \"text-block\">S7 (ab(nail) OR ti(nail) OR ab(nails) OR ti(nails))<\/div><div class = \"text-block\">S8 (ab(sliding hip screw) OR ti(sliding hip screw) OR ab(sliding hip screws) OR ti(sliding hip screws))<\/div><div class = \"text-block\">S9  S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8<\/div><div class = \"text-block\">S10 (EMB.EXACT.EXPLODE(\"bone cement\"))<\/div><div class = \"text-block\">S11 EMB.EXACT.EXPLODE(\"cementoplasty\")<\/div><div class = \"text-block\">S12 (EMB.EXACT.EXPLODE(\"poly(methyl methacrylate)\"))<\/div><div class = \"text-block\">S13 (EMB.EXACT.EXPLODE(\"calcium phosphate\"))<\/div><div class = \"text-block\">S14 (ab(cement) OR ti(cement) OR ab(cements) OR ti(cements))<\/div><div class = \"text-block\">S15 (ab(polymethyl methacrylate) OR ti(polymethyl methacrylate) OR ab(polymethyl methacrylates) OR ti(polymethyl methacrylates))<\/div><div class = \"text-block\">S16 (ab(calcium phosphates) OR ti(calcium phosphates))<\/div><div class = \"text-block\">S17 (ab(CaP) OR ti(CaP))<\/div><div class = \"text-block\">S18  S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17<\/div><div class = \"text-block\">S19  S9 AND S18<\/div><div class = \"text-block\">S20  (ab(random*) OR ti(random*)) OR (ab(placebo*) OR ti(placebo*)) OR (ab(double NEAR\/1 blind*) OR ti(double NEAR\/1 blind*))<\/div><div class = \"text-block\">S21  S19 AND S20<\/div><div class = \"text-block\">Appendix 4: ICTRP search strategy<\/div><div class = \"text-block\">( \u201cHip Fractures\u201d OR \u201cFracture Fixation\u201d OR \u201cintertrochanteric fracture\u201d<\/div><div class = \"text-block\">OR  \u201ctrochanteric fracture\u201d OR \u201cpertrochanteric fracture\u201d OR \u201cnail\u201d OR \u201csliding hip screw\u201d)<\/div><div class = \"text-block\"> AND<\/div><div class = \"text-block\">( \u201cBone Cements\u201d OR \u201cCementoplasty\u201d OR \u201cpolymethyl methacrylate\u201d OR \u201ccalcium phosphates\u201d OR \u201ccement\u201d OR \u201cpolymethyl methacrylate\u201d OR \u201ccalcium phosphates\u201d OR \u201cCaP\u201d)<\/div><div class = \"text-block\">Appendix 5: ClinicalTrials.gov search strategy<\/div><div class = \"text-block\">Condition or disease: Hip Fracture OR Fracture Fixation OR intertrochanteric fracture<\/div><div class = \"text-block\">OR  trochanteric fracture OR pertrochanteric fracture OR nail OR sliding hip screw<\/div><div class = \"text-block\">Intervention: Cement OR Cementoplasty OR polymethyl methacrylate OR calcium phosphates OR CaP<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Appendix 7<\/span><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Reference<\/span><\/div><div class = \"text-block\">1. Hagino H, Endo N, Harada A, et al. Survey of hip fractures in Japan: Recent trends in prevalence and treatment. J Orthop Sci. 2017;22(5):909-914. doi:10.1016\/j.jos.2017.06.003<\/div><div class = \"text-block\">2. Tucker A, Donnelly KJ, McDonald S, Craig J, Foster AP, Acton JD. The changing face of fractures of the hip in Northern Ireland: a 15-year review. Bone Joint J. 2017;99-B(9):1223-1231.<\/div><div class = \"text-block\">3. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the older population: injuries, healthcare costs, and long-term reduced quality of life. J Trauma. 2011;71(3):748-753.<\/div><div class = \"text-block\">4. Sommers MB, Roth C, Hall H, Kam BC, Ehmke LW, Krieg JC, Madey SM, Bottlang M. A laboratory model to evaluate cutout resistance of implants for pertrochanteric fracture fixation. J Orthop Trauma. 2004;18(6):361\u2013368.<\/div><div class = \"text-block\">5. Ehmke LW, Fitzpatrick DC, Krieg JC, Madey SM, Bottlang M. Lag screws for hip fracture fixation: evaluation of migration resistance under simulated walking. J Orthop Res. 2005;23(6):1329\u20131335.<\/div><div class = \"text-block\">6. Bojan AJ, J\u00f6nsson A, Granhed H, Ekholm C, K\u00e4rrholm J. Trochanteric fracture-implant motion during healing - A radiostereometry (RSA) study. Injury. 2018;49(3):673-679.<\/div><div class = \"text-block\">7. Kammerlander C, Gebhard F, Meier C, et al. Standardised cement augmentation of the PFNA using a perforated blade: A new technique and preliminary clinical results. A prospective multicentre trial. Injury. 2011;42(12):1484-1490.<\/div><div class = \"text-block\">8. Kammerlander C, Doshi H, Gebhard F, et al. Long-term results of the augmented PFNA: a prospective multicenter trial. Arch Orthop Trauma Surg. 2014;134(3):343-349.<\/div><div class = \"text-block\"><span>9.<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Meinberg%20EG%5BAuthor%5D&cauthor=true&cauthor_uid=29256945\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> Meinberg EG<\/span><\/a><span style = \":;:;\">,<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Agel%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29256945\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> Agel J<\/span><\/a><span style = \":;:;\">,<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Roberts%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=29256945\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> Roberts CS<\/span><\/a><span style = \":;:;\">,<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Karam%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=29256945\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> Karam MD<\/span><\/a><span style = \":;:;\">,<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Kellam%20JF%5BAuthor%5D&cauthor=true&cauthor_uid=29256945\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> Kellam JF<\/span><\/a><span>(2018) Fracture and Dislocation Classification Compendium-2018.<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Fracture+and+Dislocation+Classification+Compendium%E2%80%942018\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> J Orthop Trauma<\/span><\/a><span> 32 Suppl 1:S1-S170.<\/span><\/div><div class = \"text-block\"><span>10. Parker MJ, Palmer CR. A new mobility score for predicting mortality after hip fracture. <\/span><span style = \"font-style:italic;\">J Bone Joint Surg Br<\/span><span>. 1993;75(5):797-798.<\/span><\/div><div class = \"text-block\">11. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53\u201372.<\/div><div class = \"text-block\">12. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727\u20131736.<\/div><div class = \"text-block\">13. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. QualLife Res 2013,22;1717\u20131727.<\/div><div class = \"text-block\"><span>14. National Clinical Guideline Centre (UK). <\/span><span style = \"font-style:italic;\">The Management of Hip Fracture in Adults<\/span><span>. London: Royal College of Physicians (UK); 2011.<\/span><\/div><div class = \"text-block\">(National Institute for Health and Care Excellence (NICE) . Hip fracture management: clinical guideline, https:\/\/www.nice.org.uk\/guidance\/cg124 (2011, accessed 28 June 2020))<\/div><div class = \"text-block\"><span>15. American Academy of Orthopaedic Surgeons. Management of hip fractures in the elderly: Evidence-based clinical practice guideline.<\/span><a href=\"https:\/\/www.aaos.org\/globalassets\/quality-and-practice-resources\/hip-fractures-in-the-elderly\/hip-fractures-elderly-clinical-practice-guideline-4-24-19--2.pdf\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">https:\/\/www.aaos.org\/globalassets\/quality-and-practice-resources\/hip-fractures-in-the-elderly\/hip-fractures-elderly-clinical-practice-guideline-4-24-19--2.pdf<\/span><\/a><span>. Accessed June 28, 2020.<\/span><\/div><div class = \"text-block\"><span>16. Higgins JPT, Green S E. <\/span><span style = \"font-style:italic;\">Cochrane Handbook for Systematic Reviews of Interventions Version 6<\/span><span>. updated Ma. The Cochrane Collaboration; 2019. Available at: www.cochrane-handbook.org.<\/span><\/div><div class = \"text-block\">17. Altman DG, Bland JM. Statistics Notes Detecting skewness from summary information Lesson of the Week. 1996;313(November):1996.<\/div><div class = \"text-block\"><span>18. Furukawa T a, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. <\/span><span style = \"font-style:italic;\">J. Clin. Epidemiol.<\/span><span> 2006;59(1):7\u201310.<\/span><\/div><div class = \"text-block\"><span>19. Guyatt G, Oxman AD, Akl E a, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. <\/span><span style = \"font-style:italic;\">J. Clin. Epidemiol.<\/span><span>2011;64(4):383\u201394.<\/span><\/div><\/div>","materials":[],"description":null,"changed_on":1598709511}